eGenesis Strengthens Production Capabilities with Acquisition of ICBiotec

eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs, tissues, and cells to address the global organ shortage, today announced the acquisition of the assets and operations of ICBiotec (“ICB”), one of its key production partners. ICB is one of the few companies in the U.S. with advanced cloning and large animal transgenic production capabilities integral to the xenotransplantation supply chain. Under the terms of the transaction, eGenesis will acquire ICB’s existing facilities, equipment, and land. ICB’s research and operations staff will continue as employees of a wholly-owned subsidiary of eGenesis. The acquisition will provide eGenesis with full control of its xeno-organ supply chain.

Read the full article: eGenesis Strengthens Production Capabilities with Acquisition of ICBiotec //

Source: https://www.globenewswire.com/news-release/2020/05/20/2036359/0/en/eGenesis-Strengthens-Production-Capabilities-with-Acquisition-of-ICBiotec.html

Scroll to Top